STOCK TITAN

Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Gamida Cell (Nasdaq: GMDA) will release its financial results for Q4 and full year 2023 on March 27, 2024. The company will host a conference call and webcast to discuss the results and provide a business update.
Positive
  • None.
Negative
  • None.

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.

Following the release, management will host a conference call and live webcast at 8:30 AM Eastern Time to discuss the financial results and provide a business update.

Conference Call Dial-In & Webcast Information:

Date/Time:Wednesday, March 27, 2024 at 8:30 AM Eastern Time
Domestic:1-877-425-9470
International:1-201-389-0878
Conference ID:13744446
Call me™:Click here.
Webcast:Click here.
  

A replay of the webcast will be available on the Company’s website. approximately two hours after the event, for approximately 30 days.

About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge® (omidubicel-onlv), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram.

Omisirge® is a registered mark of Gamida Cell Inc. © 2024 Gamida Cell Inc. All Rights Reserved.

Investor Contacts:
Chuck Padala
LifeSci Advisors
chuck@lifesciadvisors.com
1-646-627-8390

Media Contact:
Dan Boyle
Orangefiery
media@orangefiery.com
1-818-209-1692

 


Gamida Cell will release its financial results for Q4 and full year 2023 on March 27, 2024.

The ticker symbol for Gamida Cell is GMDA.

The conference call and webcast to discuss the financial results will be held on March 27, 2024, at 8:30 AM Eastern Time.

The replay of the webcast will be available on the company's website for approximately 30 days, starting approximately two hours after the event.
Gamida Cell Ltd

NASDAQ:GMDA

GMDA Rankings

GMDA Latest News

GMDA Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing

About GMDA

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.